Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CARA NASDAQ:CNTB NASDAQ:COYA NASDAQ:VXRT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCARACara Therapeutics$15.19$8.13▼$19.08$24.33M0.4122,224 shs237,144 shsCNTBConnect Biopharma$2.00-1.0%$1.25$0.51▼$2.86$112.23M-0.1273,265 shs240,596 shsCOYACoya Therapeutics$6.09+2.4%$5.86$4.65▼$10.24$99.51M0.2683,647 shs39,841 shsVXRTVaxart$0.36-3.8%$0.45$0.26▼$1.07$81.45M1.143.24 million shs701,497 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCARACara Therapeutics0.00%0.00%0.00%0.00%+27.36%CNTBConnect Biopharma-0.99%-9.91%+85.19%+142.39%+68.07%COYACoya Therapeutics+2.35%-8.70%+5.36%-4.40%-11.22%VXRTVaxart-0.17%-11.05%-18.77%-20.88%-47.03%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCARACara Therapeutics0.282 of 5 stars0.00.00.04.20.00.80.0CNTBConnect Biopharma2.8446 of 5 stars3.83.00.00.02.72.50.0COYACoya Therapeutics1.9676 of 5 stars3.53.00.00.02.00.80.0VXRTVaxart3.3257 of 5 stars3.55.00.00.03.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCARACara Therapeutics 0.00N/AN/AN/ACNTBConnect Biopharma 3.50Strong Buy$7.00250.00% UpsideCOYACoya Therapeutics 3.00Buy$16.50170.94% UpsideVXRTVaxart 3.00Buy$3.00743.17% UpsideCurrent Analyst Ratings BreakdownLatest CARA, VXRT, COYA, and CNTB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/24/2025COYACoya TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.007/22/2025CNTBConnect BiopharmaNorthland CapmkSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy7/9/2025COYACoya TherapeuticsLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$16.007/1/2025COYACoya TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.006/12/2025CNTBConnect BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$7.006/9/2025COYACoya TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.005/13/2025COYACoya TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCARACara Therapeutics$7.14M0.00N/AN/A$12.58 per share0.00CNTBConnect Biopharma$26.03M4.27N/AN/A$1.67 per share1.20COYACoya Therapeutics$3.69M27.64N/AN/A$2.37 per share2.57VXRTVaxart$47.40M1.72N/AN/A$0.26 per share1.37Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCARACara Therapeutics-$118.51M-$21.01N/AN/AN/A-1,099.76%-367.97%-107.43%N/ACNTBConnect Biopharma-$15.63MN/A0.00N/AN/AN/AN/AN/A9/5/2025 (Estimated)COYACoya Therapeutics-$14.88M-$1.07N/AN/AN/AN/A-48.88%-43.32%8/11/2025 (Estimated)VXRTVaxart-$66.95M-$0.27N/AN/AN/A-122.63%-91.89%-38.40%8/14/2025 (Estimated)Latest CARA, VXRT, COYA, and CNTB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025VXRTVaxart-$0.08N/AN/AN/AN/AN/A8/11/2025Q2 2025COYACoya Therapeutics-$0.22N/AN/AN/AN/AN/A5/15/2025Q1 2025CNTBConnect Biopharma-$0.26-$0.19+$0.07-$0.19N/AN/A5/13/2025Q1 2025COYACoya Therapeutics-$0.44-$0.44N/A-$0.44$2.63 million$257.88 million5/13/2025Q1 2025VXRTVaxart-$0.07-$0.07N/A-$0.07$2.85 million$20.88 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCARACara TherapeuticsN/AN/AN/AN/AN/ACNTBConnect BiopharmaN/AN/AN/AN/AN/ACOYACoya TherapeuticsN/AN/AN/AN/AN/AVXRTVaxartN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCARACara TherapeuticsN/A4.774.71CNTBConnect Biopharma0.0110.2510.25COYACoya TherapeuticsN/A8.848.84VXRTVaxartN/A0.640.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCARACara Therapeutics44.66%CNTBConnect Biopharma58.72%COYACoya Therapeutics39.75%VXRTVaxart18.05%Insider OwnershipCompanyInsider OwnershipCARACara Therapeutics3.10%CNTBConnect Biopharma22.60%COYACoya Therapeutics12.00%VXRTVaxart2.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCARACara Therapeutics804.57 million4.43 millionOptionableCNTBConnect Biopharma11055.56 million43.00 millionOptionableCOYACoya Therapeutics616.73 million14.72 millionNot OptionableVXRTVaxart120228.91 million222.37 millionOptionableCARA, VXRT, COYA, and CNTB HeadlinesRecent News About These CompaniesVaxart, Inc. Stock (VXRT) Opinions on Reverse Stock Split ProposalJuly 31 at 1:12 PM | quiverquant.comQVaxart (NASDAQ:VXRT) Stock Price Crosses Below 200 Day Moving Average - Here's WhyJuly 29, 2025 | marketbeat.comVaxart Submits Proxy Statement for Reverse Stock Split to Support Resumption of Trading on NasdaqJuly 24, 2025 | globenewswire.comVaxart (NASDAQ:VXRT) Shares Cross Below 200-Day Moving Average - What's Next?July 19, 2025 | marketbeat.comVaxart (NASDAQ:VXRT) Share Price Crosses Below Two Hundred Day Moving Average - Here's What HappenedJuly 11, 2025 | marketbeat.comOTC Markets Group Welcomes Vaxart, Inc. to OTCQXJuly 8, 2025 | financialpost.comFVaxart (NASDAQ:VXRT) Share Price Crosses Below Two Hundred Day Moving Average - Here's WhyJuly 3, 2025 | marketbeat.comVaxart Announces Preliminary Results of Annual Meeting of StockholdersJune 13, 2025 | globenewswire.comVaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation TechnologyJune 11, 2025 | globenewswire.comVaxart, Inc. to Release Topline Data from Norovirus Phase I Trial on June 11, 2025June 10, 2025 | quiverquant.comQVaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus TrialJune 10, 2025 | globenewswire.comVaxart Announces Adjournment of Annual Meeting of StockholdersJune 2, 2025 | globenewswire.comVaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025May 29, 2025 | globenewswire.comVaxart's Dr. Sean Tucker Calls on Stockholders to Support Reverse Stock Split Proposal by June 1, 2025May 29, 2025 | quiverquant.comQVaxart's Founder and Chief Scientific Officer Provides Video Update to StockholdersMay 29, 2025 | globenewswire.comVaxart Discusses Reverse Stock Split and Capital RaiseMay 28, 2025 | tipranks.comVaxart Answers Additional Frequently Asked Questions from Retail InvestorsMay 28, 2025 | globenewswire.comVaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 TrialMay 27, 2025 | globenewswire.comVaxart Announces Adjournment of Annual Meeting of StockholdersMay 21, 2025 | globenewswire.comVaxart, Inc. Grants Equity Awards to New CFO Jeroen GrasmanMay 20, 2025 | quiverquant.comQVaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | VXRT Stock NewsMay 20, 2025 | gurufocus.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCARA, VXRT, COYA, and CNTB Company DescriptionsCara Therapeutics NASDAQ:CARACara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.Connect Biopharma NASDAQ:CNTB$2.00 -0.02 (-0.99%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.04 +0.04 (+2.00%) As of 08/1/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.Coya Therapeutics NASDAQ:COYA$6.09 +0.14 (+2.35%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$6.06 -0.04 (-0.57%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.Vaxart NASDAQ:VXRT$0.36 -0.01 (-3.84%) As of 08/1/2025 03:59 PM EasternVaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
